Monitoring of AZA/6-MP treatment in children with BD is necessary

Inflammatory Bowel Diseases

Volumn 9, Issue 6, 2003, Pages 386-388

  Dubinsky, Marla C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLTHIOINOSINE; AZATHIOPRINE; CORTICOSTEROID; DRUG METABOLITE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; PREDNISONE; STEROID; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

ARTICLE; BONE MARROW TOXICITY; CHILD CARE; CHILD DEVELOPMENT; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; ENTERITIS; GROWTH DISORDER; HUMAN; LEUKOPENIA; LIVER TOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; TREATMENT PLANNING;

6-MERCAPTOPURINE; AZATHIOPRINE; CHILD; DRUG MONITORING; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; METHYLTHIOINOSINE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; THIONUCLEOTIDES;

EID: 0344035401     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200311000-00007     Document Type: Article

References (19)

1. Corticosteroids and growth. J Pediatr. 1988;113:249-254.
2. Munkholm P. Langholz E. Davidsen M. Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
3. Markowitz J. Grancher K. Kohn N. Lesser M. Daum F. A multi-center trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119: 895-902.
4. Weinshilboum RM, Sladek SL. Mercaptopurine Pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
5. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
6. Achkar JP, Stevens T, Brzezinski A, Seidner D, Lashner B. 6-thioguanine levels versus white blood counts in guiding 6-mercaptopurine and azathioprine therapy. Am J Gastroenterol. 2000;95: 2491 A272.
7. Cuffari C. Hunt S. Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut. 2001;48:642-646.
8. Lennard L, Lilleyman JS. Variable 6-mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7:1816-1823.
9. Lennard L, Lilleyman JS. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet. 1994;343: 1188-1190.
10. Colombel JF. Ferrari N. Debuysere H. Marteau P. Gendre JP. Bonaz B. Soule JC. Modigliani R. Touze Y. Catala P. Libersa C. Broly F. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000;118:1025-1030.
11. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: A relationship between intracellular 6-MP metabolites and neutropenia. Br J Clin Pharmacol. 1983;16:358-363.
12. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46: 149-154.
13. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;341:1151.
14. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphoblastic leukemia. J Pediatr. 1991;119:985-989.
15. Black AJ, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998;129:716-718.
16. Regueiro M. Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol. 2002. 35:240-244.
17. Ewe K. Press AG. Singe CC. Stufler M. Ueberschaer B. Hommel G. Meyer zum Buschenfelde KH. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993;105:367-672.
18. Collona T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol. 1994;89:362-366.
19. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA Preliminary Evidence Suggests That 6-MP Metabolite Profiles Provide a Biochemical Explanation for 6-MP Resistance in Patients with Inflammatory Bowel Disease. Gastroenterology. 2002;122:904-915.